

Xencor reports upbeat Phase 1 kidney cancer data for XmAb819 at ESMO 2026 and selects 400 mcg/kg as the primary proposed Phase 3 study dose.
You can purchase shares of Xencor (NASDAQ:XNCR) through any online brokerage.
Other companies in Xencor’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Xencor has a consensus price target of $35.00.
The stock price for Xencor (NASDAQ: XNCR) is $30.1 last updated October 30, 2026 at 4:50 PM EDT.
There are no upcoming dividends for Xencor.
Xencor does not have any upcoming earnings scheduled.
There is no upcoming split for Xencor.
Xencor is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody...